Patent SG-11201900616U-A (SG)
Title: Engineered polypeptides and uses thereof
Inventor: VISWANATHAN KARTHIK
IPC: C07K16/10
Filed: 2017-08-02
Abstract: OO O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 March 2018 (22.03.2018) WIP0 I PCT 0111111010 0111 °nolo III m IIIII OH Immo oimIE (10) International Publication Number WO 2018/052556 Al (51) International Patent Classification: C07K 16/00 (2006.01) A61K 39/00 (2006.01) C07K 16/10 (2006.01) (21) International Application Number: PCT/US2017/045126 (22) International Filing Date: 02 August 2017 (02.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/370,201 02 August 2016 (02.08.2016) US 62/485,671 14 April 2017 (14.04.2017) US (71) Applicant: VISTERRA, INC. [US/US]; One Kendal Square, Suite B3301, Building 300, 3rd Floor, Cambridge, MA 02139 (US). (72) Inventors: VISWANATHAN, Karthik; 1 John Swift Road, Acton, MA 01720 (US). RAMAKRISHNAN, Boopathy; 605 Middle Street, Unit 19, Braintree, MA 02184 (US). BOOTH, Brain; 99 Cass Street, West Rox- bury, MA 02132 (US). NARAYAN, Kristin; 150 Maple St., Lexington, MA 02420 (US). WOLLACOTT, Andrew, M.; 16 Woodchester Drive, Milton, MA 02186 (US). (74) Agent: COLLAZO, Diana, M.; Lando & Anastadi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cam- bridge, MA 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (54) Title: ENGINEERED POLYPEPTIDES AND USES THEREOF FcRn FcRn FIG.1 (57) : Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders. In particular, Fc regions comprising either one or multiple mutations selected from the partcicular mutations disclosed in Table 1 are disclosed. Certain of said mutations result in increased affinity for the neonatal Fc receptor (FcRn), and certain of said mutations result in ehnaced half-life of engineered antibodies and also have an impact on effector functions. Particular disclosed mutations are M252Y, S254T, T256E, L309N, T250Q, M428L, N434S, N434A, T307A, E380A, N434A, M252Y, S254T, T256E, or a combination thereof as e.g. T256D/Q311V/A378V, H285N/ T307Q/N315D, H285D/T307Q/ A378V, T307Q/Q311V/A378V, T256D/ N286D/T307R/Q311V/A378V, or T256D/T307R/Q311. [Continued on next page] WO 2018/052556 Al MIDEDIMOMOIDEIREEMOOMMEIHMOROMEEN OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))